News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,696 Results
Type
Article (87415)
Company Profile (739)
Press Release (770524)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232780)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91178)
Employer Resources (205)
FDA (18254)
Job Trends (17422)
News (396872)
Policy (39845)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (120)
Alliances (56801)
ALS (153)
Alzheimer's disease (1752)
Antibody-drug conjugate (ADC) (312)
Approvals (18383)
Artificial intelligence (470)
Autoimmune disease (155)
Automation (33)
Bankruptcy (402)
Best Places to Work (12515)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (540)
Cancer (4297)
Cardiovascular disease (306)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (762)
Cervical cancer (30)
Clinical research (76134)
Collaboration (1615)
Company closure (4)
Compensation (992)
Complete response letters (64)
COVID-19 (2929)
CRISPR (87)
C-suite (732)
Cystic fibrosis (143)
Data (5450)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (342)
Diagnostics (6983)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (253)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (213)
Earnings (98034)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132955)
Executive appointments (826)
FDA (20666)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1277)
Gene editing (186)
Generative AI (46)
Gene therapy (607)
GLP-1 (933)
Government (5325)
Grass and pollen (4)
Guidances (281)
Healthcare (20785)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (59)
Indications (81)
Infectious disease (3151)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (96)
Intellectual property (201)
Interviews (816)
IPO (17811)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10093)
Liver cancer (87)
Longevity (13)
Lung cancer (587)
Lymphoma (335)
Machine learning (41)
Management (66)
Manufacturing (718)
MASH (161)
Medical device (14440)
Medtech (14471)
Mergers & acquisitions (22746)
Metabolic disorders (1067)
Multiple sclerosis (151)
NASH (22)
Neurodegenerative disease (330)
Neuropsychiatric disorders (79)
Neuroscience (2897)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5082)
Now hiring (65)
Obesity (522)
Opinion (325)
Ovarian cancer (151)
Pain (157)
Pancreatic cancer (170)
Parkinson's disease (261)
Partnered (33)
Patents (397)
Patient recruitment (417)
Peanut (56)
People (66300)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23601)
Phase 2 (33133)
Phase 3 (24827)
Pipeline (4323)
Policy (285)
Postmarket research (3544)
Preclinical (10592)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (279)
Rare diseases (802)
Real estate (7422)
Recruiting (80)
Regulatory (28267)
Reports (64)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (64)
Schizophrenia (139)
Series A (226)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4325)
State (2)
Stomach cancer (14)
Supply chain (75)
Tariffs (76)
The Weekly (122)
Vaccines (1000)
Venture capital (91)
Weight loss (339)
Women's health (72)
Worklife (22)
Date
Today (16)
Last 7 days (482)
Last 30 days (1632)
Last 365 days (25489)
2026 (2421)
2025 (25794)
2024 (34163)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1280)
Alabama (85)
Alaska (6)
Arizona (290)
Arkansas (8)
Asia (51145)
Australia (9005)
California (9779)
Canada (2507)
China (1058)
Colorado (315)
Connecticut (391)
Delaware (295)
Europe (116963)
Florida (1265)
Georgia (257)
Hawaii (4)
Idaho (65)
Illinois (663)
India (58)
Indiana (451)
Iowa (22)
Japan (344)
Kansas (133)
Kentucky (25)
Louisiana (15)
Maine (59)
Maryland (1262)
Massachusetts (7355)
Michigan (254)
Minnesota (455)
Mississippi (5)
Missouri (78)
Montana (29)
Nebraska (29)
Nevada (106)
New Hampshire (58)
New Jersey (2569)
New Mexico (29)
New York (2574)
North Carolina (1426)
North Dakota (9)
Northern California (4791)
Ohio (260)
Oklahoma (18)
Oregon (52)
Pennsylvania (1882)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (15)
South Dakota (1)
Southern California (3767)
Tennessee (62)
Texas (1381)
United States (34082)
Utah (214)
Vermont (1)
Virginia (179)
Washington D.C. (55)
Washington State (828)
West Virginia (2)
Wisconsin (82)
858,696 Results for "formation bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Formation Bio Licenses miR-124 Activator for Autoimmune Diseases from CTFH
January 30, 2026
·
3 min read
Press Releases
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
December 11, 2025
·
4 min read
Press Releases
Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals
December 11, 2025
·
4 min read
Artificial intelligence
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.
June 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
September 18, 2025
·
3 min read
Press Releases
Libertas Bio, a Formation Bio subsidiary, License of Gusacitinib, a Dual JAK/SYK Inhibitor, to Sanofi
June 23, 2025
·
2 min read
Press Releases
IMU Biosciences announces formation of Scientific Advisory Board
November 13, 2025
·
5 min read
Press Releases
Climb Bio to Present at Upcoming Investor Conferences - February 5, 2026
February 5, 2026
·
1 min read
Press Releases
SAB BIO to Participate in Upcoming February 2026 Investor Conferences
February 5, 2026
·
1 min read
Press Releases
Biocoat Announces Formation of Surmodics Services & Technologies Division Following Merger and Divestiture Transactions
December 11, 2025
·
2 min read
1 of 85,870
Next
